EBOS Group Toekomstige groei

Future criteriumcontroles 1/6

EBOS Group zal naar verwachting groeien in winst en omzet met respectievelijk 6.9% en 1% per jaar. De winst per aandeel zal naar verwachting groeien met 6.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.9% zijn.

Belangrijke informatie

6.9%

Groei van de winst

6.3%

Groei van de winst per aandeel

Healthcare winstgroei	25.1%
Inkomstengroei	1.0%
Toekomstig rendement op eigen vermogen	12.9%
Dekking van analisten	Good
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

CHIA:EBO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	12,933	330	349	424	11
6/30/2026	12,330	298	320	394	12
6/30/2025	11,711	261	277	417	12
6/30/2024	13,189	272	229	348	N/A
3/31/2024	12,932	264	218	342	N/A
12/31/2023	12,674	257	206	336	N/A
9/30/2023	12,456	255	250	364	N/A
6/30/2023	12,237	253	293	391	N/A
3/31/2023	11,933	243	258	347	N/A
12/31/2022	11,629	233	222	303	N/A
9/30/2022	11,182	218	191	276	N/A
6/30/2022	10,734	203	159	249	N/A
3/31/2022	10,267	198	175	278	N/A
12/31/2021	9,800	194	190	306	N/A
9/30/2021	9,502	190	203	302	N/A
6/30/2021	9,203	185	216	298	N/A
3/31/2021	9,123	180	222	276	N/A
12/31/2020	9,043	174	228	254	N/A
9/30/2020	8,904	168	214	241	N/A
6/30/2020	8,766	163	200	229	N/A
3/31/2020	8,288	157	161	191	N/A
12/31/2019	7,810	152	121	153	N/A
9/30/2019	7,370	145	103	136	N/A
6/30/2019	6,930	138	84	119	N/A
3/31/2019	6,909	136	74	115	N/A
12/31/2018	6,888	134	64	110	N/A
9/30/2018	6,937	136	84	136	N/A
6/30/2018	6,987	137	104	162	N/A
3/31/2018	7,016	134	N/A	172	N/A
12/31/2017	6,927	129	N/A	179	N/A
9/30/2017	6,998	126	N/A	157	N/A
6/30/2017	7,271	127	N/A	137	N/A
3/31/2017	7,023	122	N/A	169	N/A
12/31/2016	7,396	127	N/A	217	N/A
9/30/2016	7,033	123	N/A	214	N/A
6/30/2016	6,797	122	N/A	215	N/A
3/31/2016	6,057	110	N/A	169	N/A
12/31/2015	5,957	109	N/A	141	N/A
9/30/2015	5,641	101	N/A	129	N/A
6/30/2015	5,343	93	N/A	118	N/A
3/31/2015	5,868	100	N/A	112	N/A
12/31/2014	5,608	92	N/A	91	N/A
9/30/2014	5,182	84	N/A	93	N/A
6/30/2014	5,345	85	N/A	106	N/A
3/31/2014	4,598	72	N/A	89	N/A
12/31/2013	3,746	58	N/A	69	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei EBO ( 6.9% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van EBO ( 6.9% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 12.4% per jaar).

Hoge groeiwinsten: De winst van EBO zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van EBO ( 1% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 5.7% per jaar).

Hoge groei-inkomsten: De omzet van EBO ( 1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen EBO zal naar verwachting over 3 jaar laag zijn ( 12.9 %).

EBOS Group Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

EBOS Group Limited Announces the Retirement of Peter Williams as Director

Final dividend of NZ$0.64 announced

EBOS Group Limited Announces Final Dividend, Payable on 18 September 2024

Full year 2024 earnings released: EPS: AU$1.41 (vs AU$1.33 in FY 2023)

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.

Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk

Now 23% undervalued

EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit

EBOS Not to Proceed with Acquisition in Animal Care Segment

EBOS Not to Proceed with Acquisition in Animal Care Segment

Now 21% undervalued

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023

Now 21% undervalued

Upcoming dividend of NZ$0.60 per share at 3.0% yield

Ebos Group Limited Announces Dividend, Payable on 29 September 2023

Full year 2023 earnings released: EPS: AU$1.33 (vs AU$1.15 in FY 2022)

Investor sentiment deteriorates as stock falls 18%

Now 26% undervalued after recent price drop

First half 2023 earnings released: EPS: AU$0.70 (vs AU$0.61 in 1H 2022)

EBOS Group Limited to Report Q2, 2023 Results on Feb 22, 2023

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Upcoming dividend of NZ$0.51 per share

Full year 2022 earnings released: EPS: AU$1.15 (vs AU$1.13 in FY 2021)

EBOS Group Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 30 September, 2022

Upcoming dividend of NZ$0.49 per share

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2021, Payable on Sept. 24, 2021

Upcoming dividend of NZ$0.48 per share

EBOS Group Limited (EBOS) acquired Sentry Medical.

Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020)

EBOS Group Limited (NZSE:EBO) acquired Pioneer Medical Limited for AUD 40 million.

Upcoming Dividend of NZ$0.44 Per Share

Revenue beats expectations

First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020)

EBOS Group Limited (NZSE:EBO) acquired Vet Distribution Business of Clifford Hallam Healthcare Pty Ltd for AUD 9.2 million.

EBOS Group Limited (NZSE:EBO) acquired CH2 Vet for AUD 9.2 million.

New 90-day high: AU$28.30

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

New 90-day high: AU$28.29

New 90-day high: AU$25.38

EBOS Group Limited (NZSE:EBO) entered into an agreement to acquire Cryomed Aesthetics Pty Limited for AUD 14.1 million.

New 90-day high: AU$23.21

New 90-day high - AU$22.30

New 90-day high - AU$21.36

Full year earnings released

New 90-day low - AU$20.17

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven